United States· US:0310-3512_7365aa18-60da-4ce6-9c06-01c80e158286
CALQUENCE
A acalabrutinib product containing acalabrutinib, registered in United States by AstraZeneca Pharmaceuticals LP. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Acalabrutinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EL02 (acalabrutinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Acalabrutinib · ATC L01EL02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of acalabrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $190.74 in Switzerland — a ×1172 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Acalabrutinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$190.74
- FR France$0.16
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ACALABRUTINIB
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Country
- United States (US)
- ATC code
- L01EL02
- ATC class
- Acalabrutinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc11031035126060 TABLET, FILM COATED in 1 BOTTLE (0310-3512-60)
- ndc11031035129560 TABLET, FILM COATED in 1 BLISTER PACK (0310-3512-95)
- ndc110310-3512-60
- ndc110310-3512-95
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for acalabrutinib.
Graded by severity as the source publishes them — 201 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acalabrutinib · interactions on record
375 records
- 201 severe
- 174 moderate
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Acalabrutinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCALQUENCE 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- CzechiaCALQUENCEAstraZeneca AB, Södertälje
- FinlandCalquenceAstraZeneca AB
- FranceCALQUENCE 100 mg, comprimé pelliculéASTRAZENECA AB
- IcelandCalquenceAstraZeneca AB*
- NetherlandsCalquence 100 mg, filmomhulde tablettenAstraZeneca AB
- NorwayCalquenceAstraZeneca AB
- PolandCalquenceAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Calquence
- Liechtenstein · Calquence
- Norway · Calquence
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9c747503-501c-4b16-adfc-9875f884f83c GET /v1/drugs/9c747503-501c-4b16-adfc-9875f884f83c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "ACALABRUTINIB",
"productndc": "0310-3512",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA216387",
"marketing_category": "NDA"
}See everything about acalabrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.